Corcept Therapeutics Incorporated (CORT) Insider Robert S. Fishman Sells 8,000 Shares
Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Robert S. Fishman sold 8,000 shares of the company’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $14.57, for a total value of $116,560.00. Following the sale, the insider now owns 8,000 shares of the company’s stock, valued at $116,560. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of CORT stock traded up $0.09 on Tuesday, hitting $14.57. 1,055,400 shares of the company’s stock were exchanged, compared to its average volume of 1,528,712. Corcept Therapeutics Incorporated has a 12 month low of $11.55 and a 12 month high of $25.96. The company has a market cap of $1.72 billion, a P/E ratio of 32.70 and a beta of 1.55.
Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.04). Corcept Therapeutics had a return on equity of 38.53% and a net margin of 68.32%. The business had revenue of $62.31 million for the quarter, compared to the consensus estimate of $68.49 million. During the same quarter in the prior year, the company earned $0.13 earnings per share. Corcept Therapeutics’s quarterly revenue was up 75.2% compared to the same quarter last year. analysts anticipate that Corcept Therapeutics Incorporated will post 0.6 EPS for the current year.
A number of analysts have recently weighed in on the company. ValuEngine downgraded Corcept Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, August 13th. B. Riley cut their target price on Corcept Therapeutics from $30.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, August 13th. BidaskClub downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, July 14th. Finally, Stifel Nicolaus downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 target price for the company. in a research report on Thursday, May 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Corcept Therapeutics has a consensus rating of “Buy” and an average price target of $21.83.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.
Featured Story: Price to Earnings Ratio (PE), For Valuing Stocks
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.